News headlines about Savara (NASDAQ:SVRA) have been trending somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Savara earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave press coverage about the company an impact score of 47.8047997110764 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news stories that may have impacted Accern’s analysis:
SVRA stock traded down $0.20 during midday trading on Friday, reaching $8.61. 87,850 shares of the company were exchanged, compared to its average volume of 178,009. The company has a current ratio of 16.28, a quick ratio of 16.28 and a debt-to-equity ratio of 0.13. Savara has a 1-year low of $4.60 and a 1-year high of $17.19. The stock has a market cap of $263.44, a P/E ratio of -4.89 and a beta of 0.04.
Savara (NASDAQ:SVRA) last released its quarterly earnings data on Wednesday, March 14th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.02. equities research analysts predict that Savara will post -1.43 earnings per share for the current year.
Several analysts recently weighed in on the stock. BidaskClub cut shares of Savara from a “sell” rating to a “strong sell” rating in a report on Friday, March 30th. ValuEngine cut shares of Savara from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. Canaccord Genuity set a $25.00 target price on shares of Savara and gave the company a “buy” rating in a report on Friday, February 16th. Finally, Ladenburg Thalmann started coverage on shares of Savara in a report on Wednesday, January 3rd. They set a “buy” rating and a $35.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $23.58.
In other news, insider Jaakko Taneli Jouhikainen sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $12.85, for a total transaction of $321,250.00. Following the transaction, the insider now directly owns 219,216 shares in the company, valued at $2,816,925.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Yuri Pikover bought 3,734 shares of the stock in a transaction dated Thursday, March 29th. The shares were acquired at an average price of $9.00 per share, for a total transaction of $33,606.00. Following the completion of the transaction, the director now owns 153,734 shares of the company’s stock, valued at approximately $1,383,606. The disclosure for this purchase can be found here. 6.93% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Savara (SVRA) Share Price” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/08/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-savara-svra-share-price.html.
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.